Annual Report 2013 of Square Pharmaceuticals Limited

It is a broadly described annual report of Square Pharmaceuticals Limited in the year of 2012-2013. The company contributed an amount of Taka. 4,346,954,149 (including Tk. 132,466,993 as contribution as duty/taxes towards machinery & spare parts imports) to National Exchequer as against Taka. 3,901,754,041 in the previous year. During the financial year, The Company’s Gross Turnover Tk. 20,742,746,372. Cost of Goods Sold Tk. 10,223,478,073 Gross Profit Tk. 7,736,011,423 Profit before tax Tk. 4,481,047,443. Net Profit after Tax for the year Tk. 3,341,424,783. The Earning per Share of Tk. 9.01 is based on increased outstanding 370,768,664 shares of Tk. 10 each. However, if the original issued capital at the time of IPO is considered, the EPS would stand at Tk. 334.14 in 2012-2013 as against Tk. 289.77 in 2011-2012.

The Board of Directors proposed and recommended for the declaration of Cash Dividend @25% for the year 2012-2013. The Board also recommended for the declaration of Stock Dividend (Bonus Shares) @30%. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Square Pharmaceuticals Limited: